Leticia De Mattos-Arruda

Address Vall d'Hebron Institute of Oncology (VHIO)
Country

Spain

Leticia De Mattos Arruda

Dr Leticia De Mattos-Arruda, MD, PhD is a physician scientist medical oncologist at the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. She worked at the VHIO conducting clinical trials and translational research projects from 2009 to 2014. In 2010, she was a recipient of the European Society for Medical Oncology (ESMO) Translational Research Fellowship and attended the 12o ECCO - AACR - EORTC - ESMO Workshop on Methods in Clinical Cancer Research with a special grant from the Ontario Institute of Cancer Research. In 2012 and 2013, she received Merit Awards from ASCO Conquer Cancer Foundation; in 2014, AACR Scholar-In-Training Award in the San Antonio Breast Cancer Symposium, and in 2014 she was awarded the ‘Advanced Program in Oncology’ grant by the ‘Asociación Española Contra el Cáncer’. 

She obtained Masters and PhD degrees from the Universitat Autonoma de Barcelona, Spain. Following completion of her Fellowship in Vall d’Hebron in 2014, she took up a position as a Visiting Scientist at the Memorial Sloan-Kettering Cancer Center, New York, US (Dr. Reis-Filho laboratory). From 2015 to 2017, she was a Visiting Scientist at Cancer Research UK in Dr Carlos Caldas’ laboratory at the Cambridge Institute to work with clonal and cellular heterogeneity across breast cancer metastatic sites and across the neoadjuvant breast cancer setting.

Leticia returned to Spain and in 2017 she was appointed Group Leader / Principal Investigator at the Vall d' Hebron Institute of Oncology.

In 2017, she was selected for the “Leaders Generation Program” of ESMO. She is a member of ESMO, ASCO, EACR, AACR and, from 2012 to 2017, she was an active member of the ESMO Young Oncologist Committee. She is a faculty member for breast cancer field for ESMO, and a member of the Editorial Board in the field of Breast Cancer 2018 / 2019 of "ESMO Open - Cancer Horizons" journal of ESMO.

Leticia’s main areas of interest are translational research in breast cancer metastasis, investigating tumour genomic and microenvironment heterogeneity and liquid biopsies.